<b><i>Acquisitions </i></b><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">The accounting for acquisitions requires extensive use of estimates and judgments to measure the fair value of the identifiable tangible and intangible assets acquired, including in-process research and
development, and </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">68 </font></p><p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p align="justify" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">
liabilities assumed. Additionally, we must determine whether an acquired entity is considered to be a business or a set of net assets, because the excess of the purchase price over the fair value
of net assets acquired can only be recognized as goodwill in a business combination.</font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">On July1, 2010, we
completed a business combination agreement and effected a revised distribution agreement with our distributor in Turkey.We paid $33.0 million for the termination of the original distribution agreement and purchased the commercial assets
related to the selling of our products in Turkey for $6.1 million in cash and estimated contingent consideration of $36.7 million as of the acquisition date.On January15, 2010, we acquired Serica Technologies, Inc., or Serica, for an
aggregate purchase price of approximately $63.7million, net of cash acquired.On July7, 2009, we acquired a 50.001% stockholder interest in a joint venture, Samil Allergan Ophthalmic Joint Venture Company, or Samil, for
approximately $14.8 million, net of cash acquired.We accounted for these acquisitions as business combinations.The tangible and intangible assets acquired and liabilities assumed in connection with these acquisitions were recognized
based on their estimated fair values at the acquisition dates.The determination of estimated fair values requires significant estimates and assumptions including, but not limited to, determining the timing and estimated costs to complete the
in-process projects, projecting regulatory approvals, estimating future cash flows and developing appropriate discount rates.We believe the estimated fair values assigned to the assets acquired and liabilities assumed are based on reasonable
assumptions.</font></p><p style="margin-top:12px;margin-bottom:0px; margin-left:4%"><font size="2" style="font-family:Times New Roman"><b><i>Impairment Evaluations for Goodwill and Purchased Intangible Assets </i></b></font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">We evaluate goodwill for impairment on an annual basis, or more frequently if we believe indicators of impairment exist,
by comparing the carrying value of each of our reporting units to their estimated fair value.We have identified two reporting units, specialty pharmaceuticals and medical devices, and currently perform our annual evaluation as of
October1 each year.</font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">We primarily use the income approach and the market approach to valuation that
include the discounted cash flow method, the guideline company method, as well as other generally accepted valuation methodologies to determine the fair value of our reporting units.Upon completion of the October 2010 annual impairment
assessment, we determined that no impairment was indicated as the estimated fair value of each of the two reporting units exceeded its respective carrying value.As of December31, 2010, we do not believe any significant indicators of
impairment exist for our goodwill that would require additional analysis.</font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">We also review purchased intangible
assets for impairment when events or changes in circumstances indicate that the carrying value of our intangible assets may not be recoverable.An impairment in the carrying value of an intangible asset is recognized whenever anticipated future
undiscounted cash flows from an intangible asset are estimated to be less than its carrying value.</font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><font size="2" style="font-family:Times New Roman">In the third quarter of 2010, we concluded that the intangible assets and a related prepaid royalty asset associated with the <i>Sanctura</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> franchise, or the
<i>Sanctura</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> Assets, which we acquired in connection with our 2007 acquisition of Esprit Pharma Holding
Company, Inc., or Esprit, and certain subsequent licensing and commercialization transactions, had become impaired.We determined that an impairment charge was required with respect to the <i>Sanctura</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> Assets because the estimated undiscounted future cash flows over their remaining useful life were not sufficient to
recover the current carrying amount of the <i>Sanctura</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> Assets and the carrying amount exceeded the
estimated fair value of those assets due to a reduction in expected future financial performance for the
<i>Sanctura</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> franchise resulting from lower than anticipated acceptance by patients, physicians and
payors.As a result, in the third quarter of 2010, we recorded an aggregate charge of $369.1 million related to the impairment of the <i>Sanctura</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> Assets and related costs, which includes a charge of $343.2 million for the impairment of the <i>Sanctura</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> intangible assets.We did not record any impairment charges in 2009. In 2008, we recorded a pre-tax impairment charge of $5.6 million for an intangible asset
related to the phase out of a collagen product. </font></p><i>Sanctura</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><i>Sanctura</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><i>Sanctura</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><i>Sanctura</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><i>Sanctura</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><i>Sanctura</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><i>Sanctura</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">69 </font></p><p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p align="justify" style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">Significant management judgment is required in the forecasts of future
operating results that are used in our impairment evaluations.The estimates we have used are consistent with the plans and estimates that we use to manage our business.It is possible, however, that the plans may change and estimates used
may prove to be inaccurate. If our actual results, or the plans and estimates used in future impairment analyses, are lower than the original estimates used to assess the recoverability of these assets, we could incur future impairment charges.
</font></p><p style="margin-top:12px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>Operations </b></font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">Headquartered in Irvine, California, we are a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics, medical devices and
over-the-counter products that enable people to live life to its greatest potential  to see more clearly, move more freely and express themselves more fully.Our diversified approach enables us to follow our research and development into
new specialty areas where unmet needs are significant.</font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">We discover, develop and commercialize specialty
pharmaceutical, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in more than 100
countries around the world.We are a pioneer in specialty pharmaceutical research, targeting products and technologies related to specific disease areas such as chronic dry eye, glaucoma, retinal disease, psoriasis, acne, movement disorders,
neuropathic pain and genitourinary diseases. Additionally, we are a leader in discovering, developing and marketing therapeutic and aesthetic biological, pharmaceutical and medical device products, including saline and silicone gel breast implants,
dermal fillers and obesity intervention products.At December31, 2010, we employed approximately 9,200persons around the world.Our principal markets are the United States, Europe, Latin America and Asia Pacific.</font></p><p style="margin-top:12px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>Results of Operations </b></font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><font size="2" style="font-family:Times New Roman">We operate our business on the basis of two reportable segments specialty pharmaceuticals and medical devices.The specialty pharmaceuticals segment produces a broad range of
pharmaceutical products, including: ophthalmic products for dry eye, glaucoma, retinal diseases and ocular surface disease; <i>Botox</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and other prescription and over-the-counter skin care
products; and urologics products.The medical devices segment produces a broad range of medical devices, including: breast implants for augmentation, revision and reconstructive surgery; obesity intervention products, including the
<i>Lap-Band</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> System and the <i>Orbera</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> Intragastric Balloon System; and facial aesthetics products.We provide global marketing strategy teams to coordinate the development and execution of a
consistent marketing strategy for our products in all geographic regions that share similar distribution channels and customers. </font></p><i>Botox</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><i>Lap-Band</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><i>Orbera</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">Management evaluates our business segments and various global product portfolios on a revenue basis, which is presented below in accordance with GAAP.We also report sales performance using the
non-GAAP financial measure of constant currency sales.Constant currency sales represent current period reported sales, adjusted for the translation effect of changes in average foreign exchange rates between the current period and the
corresponding period in the prior year.We calculate the currency effect by comparing adjusted current period reported sales, calculated using the monthly average foreign exchange rates for the corresponding period in the prior year, to the
actual current period reported sales.We routinely evaluate our net sales performance at constant currency so that sales results can be viewed without the impact of changing foreign currency exchange rates, thereby facilitating period-to-period
comparisons of our sales.Generally, when the U.S.dollar either strengthens or weakens against other currencies, the growth at constant currency rates will be higher or lower, respectively, than growth reported at actual exchange rates.
</font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">70 </font></p><p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p align="justify" style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">The following table compares net sales by product line within each
reportable segment and certain selected pharmaceutical products for the years ended December31, 2010, 2009 and 2008: </font></p><p style="font-size:12px;margin-top:0px;margin-bottom:0px"></p><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td width="74%"></td>
<td valign="bottom" width="1%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="1%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="1%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="1%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="1%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="1%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="1%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="6" style="border-bottom:1px solid #000000" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>YearEndedDecember31,</b></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="10" style="border-bottom:1px solid #000000" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>Change in Product Net Sales</b></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="10" style="border-bottom:1px solid #000000" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>PercentChangeinProductNetSales</b></font></td>
<td valign="bottom"><font size="1"></font></td></tr>
<tr>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" style="border-bottom:1px solid #000000" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>2010</b></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" style="border-bottom:1px solid #000000" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>2009</b></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" style="border-bottom:1px solid #000000" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>Total</b></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" style="border-bottom:1px solid #000000" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>Performance</b></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" style="border-bottom:1px solid #000000" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>Currency</b></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" style="border-bottom:1px solid #000000" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>Total</b></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" style="border-bottom:1px solid #000000" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>Performance</b></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" style="border-bottom:1px solid #000000" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>Currency</b></font></td>
<td valign="bottom"><font size="1"></font></td></tr>
<tr>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="18" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>(inmillions)</b></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td colspan="2" valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td colspan="2" valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td colspan="2" valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Net Sales by Product Line:</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td></tr>
<tr>
<td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Specialty Pharmaceuticals:</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Eye Care Pharmaceuticals</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">2,262.0</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">2,100.6</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">161.4</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">146.5</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">14.9</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">7.7%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">7.0%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">0.7%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman"><i>Botox</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font>/Neuromodulator
</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">1,419.4</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">1,309.6</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">109.8</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">93.0</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">16.8</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">8.4%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">7.1%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">1.3%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Skin Care</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">229.5</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">208.0</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">21.5</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">21.0</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">0.5</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">10.3%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">10.1%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">0.2%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr>
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Urologics</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">62.5</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">65.6</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(3.1</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(3.1</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(4.7)%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(4.7)%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:4.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Total Specialty<br/>Pharmaceuticals</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">3,973.4</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">3,683.8</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">289.6</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">257.4</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">32.2</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">7.9%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">7.0%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">0.9%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td></tr>
<tr>
<td valign="top"> <p style="margin-left:2.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Medical Devices:</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Breast Aesthetics</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">319.1</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">287.5</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">31.6</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">31.9</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(0.3</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">11.0%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">11.1%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(0.1)%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr>
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Obesity Intervention</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">243.3</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">258.2</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(14.9</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(18.2</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">3.3</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(5.8)%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(7.0)%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">1.2%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:3.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Facial Aesthetics</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">283.8</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">218.1</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">65.7</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">62.2</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">3.5</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">30.1%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">28.5%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">1.6%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td></tr>
<tr>
<td valign="top"> <p style="margin-left:4.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Total Medical Devices</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">846.2</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">763.8</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">82.4</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">75.9</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">6.5</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">10.8%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">9.9%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">0.9%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td></tr>
<tr>
<td height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Total product net sales</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">4,819.6</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">4,447.6</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">372.0</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">333.3</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">38.7</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">8.4%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">7.5%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">0.9%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td></tr>
<tr>
<td height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Domestic product net sales</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">62.6</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">%</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">65.4</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">%</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">International product net sales</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">37.4</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">%</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">34.6</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">%</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td></tr>
<tr>
<td height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman"><i></i>Selected Product Net Sales (a):<i></i></font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman"><i>Alphagan</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><i>P</i>,
<i>Alphagan</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> and<i>Combigan</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font></font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">401.6</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">414.5</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(12.9</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(15.6</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">2.7</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(3.1)%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(3.8)%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">0.7%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman"><i>Lumigan</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> Franchise</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">526.7</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">456.5</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">70.2</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">71.3</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(1.1</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">15.4%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">15.6%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(0.2)%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman"><i>Restasis</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font></font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">620.5</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">522.9</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">97.6</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">96.7</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">0.9</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">18.7%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">18.5%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">0.2%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman"><i>Sanctura</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> Franchise</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">62.5</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">65.6</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(3.1</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(3.1</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(4.7)%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">(4.7)%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman"><i>Latisse</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font></font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">81.8</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">73.7</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">8.1</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">7.6</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">0.5</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">11.0%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">10.4%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" valign="bottom"><font size="2" style="font-family:Times New Roman">0.6%</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr></table><br /><hr noshade=""/><hr noshade=""/><br /><b><i>Acquisitions </i></b><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">The accounting for acquisitions requires extensive use of estimates and judgments to measure the fair value of the
identifiable tangible and intangible assets acquired, including in-process research and development, and liabilities assumed. Additionally, the Company must determine whether an acquired entity is considered to be a business or a set of net assets,
because the excess of the purchase price over the fair value of net assets acquired can only be recognized as goodwill in a business combination.</font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">On July1, 2010, the Company completed a business combination agreement and effected a revised distribution agreement with its distributor in Turkey.The Company paid $33.0 million for the
termination of the original distribution agreement and purchased the commercial assets related to the selling of the Companys products in Turkey for $6.1 million in cash and estimated contingent consideration of $36.7 million as of the
acquisition date.On January15, 2010, the Company acquired Serica Technologies, Inc. (Serica) for an aggregate purchase price of approximately $63.7million, net of cash acquired.On July7, 2009, the Company acquired a
50.001% stockholder interest in a joint venture, Samil Allergan Ophthalmic Joint Venture Company (Samil), for approximately $14.8 million, net of cash acquired.The Company accounted for these acquisitions as business combinations.The
tangible and intangible assets acquired and liabilities assumed in connection with these </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">F-11
</font></p><p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>ALLERGAN, INC. </b></font></p><p align="center" style="margin-top:6px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS  (Continued) </b></font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="justify" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">
acquisitions were recognized based on their estimated fair values at the acquisition dates.The determination of estimated fair values requires significant estimates and assumptions
including, but not limited to, determining the timing and estimated costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows, and developing appropriate discount rates.The Company believes the
estimated fair values assigned to the assets acquired and liabilities assumed are based on reasonable assumptions.</font></p><p style="margin-top:12px;margin-bottom:0px; margin-left:4%"><font size="2" style="font-family:Times New Roman"><b><i>Comprehensive Income (Loss) </i></b></font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">Comprehensive income (loss) encompasses all changes in equity other than those with stockholders and consists of net earnings (losses), foreign currency translation adjustments, certain pension and other
postretirement benefit plan adjustments, unrealized gains or losses on marketable equity investments and unrealized and realized gains or losses on derivative instruments, if applicable. The Company does not recognize U.S.income taxes on
foreign currency translation adjustments since it does not provide for such taxes on undistributed earnings of foreign subsidiaries. </font></p><p style="margin-top:12px;margin-bottom:0px; margin-left:4%"><font size="2" style="font-family:Times New Roman"><b><i>Reclassifications </i></b></font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">Certain reclassifications of
prior year amounts have been made to conform with the current year presentation. </font></p><p style="margin-top:12px;margin-bottom:0px; margin-left:4%"><font size="2" style="font-family:Times New Roman"><b><i>Recently Adopted Accounting Standards
</i></b></font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">In June 2009, the Financial Accounting Standards Board (FASB) issued authoritative guidance that
requires companies to perform a qualitative analysis to determine whether a variable interest in another entity represents a controlling financial interest in a variable interest entity. A controlling financial interest in a variable interest entity
is characterized by having both the power to direct the most significant activities of the entity and the obligation to absorb losses or the right to receive benefits of the entity.This guidance also requires ongoing reassessments of variable
interests based on changes in facts and circumstances.This guidance became effective for fiscal years beginning after November15, 2009.The Company adopted the provisions of the guidance in the first quarter of 2010 and determined
that as of December31, 2010, the Company holds a variable interest in one variable interest entity (VIE) for which the Company is not the primary beneficiary. </font></p><p style="margin-top:12px;margin-bottom:0px; margin-left:4%"><font size="2" style="font-family:Times New Roman"><b><i>New Accounting Standards Not Yet Adopted </i></b></font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">In
December 2010, the FASB issued an accounting standards update that provides guidance on the recognition and classification of the annual fee imposed by the Patient Act and Affordable Care Act as amended by the Health Care and Education
Reconciliation Act on pharmaceutical companies that manufacture or import branded prescription drugs.Under this guidance, the annual fee should be estimated and recognized in full as a liability upon the first qualifying sale with a
corresponding deferred cost that is amortized to operating expense using a straight-line method of allocation unless another method better allocates the fee over the calendar year in which it is payable. The annual fee ranges from $2.5 billion to
$4.1 billion for all affected entities in total, a portion of which will be allocated to the Company on the basis of the amount of its branded prescription drug sales for the preceding year as a percentage of the industrys branded prescription
drug sales for the same period. The annual fee is not deductible for federal income tax purposes. This guidance will be effective for calendar years beginning after December31, 2010, which will be the Companys fiscal year 2011. The
Company currently estimates the annual fee for 2011 to be approximately $20.0 million.</font></p><br /><hr noshade=""/><hr noshade=""/><br /><b>Note2:Acquisitions and Collaborations</b><b> </b><p style="margin-top:12px;margin-bottom:0px; margin-left:4%"><font size="2" style="font-family:Times New Roman"><b><i>Purchase of Distributors Business in Turkey </i></b></font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">On July1, 2010, the Company terminated its existing distributor agreement in Turkey and completed the purchase from
its distributor of all licenses, registrations and other assets related to the selling of the Companys products in Turkey. Additionally, former employees of the distributor who were primarily engaged in the selling and marketing of the
Companys products were transferred to the Company on that date.The termination of the existing distributor agreement and purchase of the commercial assets enabled the Company to initiate direct selling operations in Turkey.</font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">In conjunction with the termination of the existing distributor agreement, the Company paid $33.0 million, including a
termination fee and related taxes, which is included in selling, general and administrative (SG&amp;A) expenses in the third quarter of 2010.The purchase of the commercial assets was accounted for as a business combination. In connection with
the purchase of the assets, the Company paid $6.1 million and is required to pay </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">F-13
</font></p><p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>ALLERGAN, INC. </b></font></p><p align="center" style="margin-top:6px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS  (Continued) </b></font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="justify" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">
additional contingent consideration based on specified percentages of revenue in Turkey over the next five years.The estimated fair value of the contingent consideration as of the
acquisition date was $36.7 million.The Company recognized goodwill of $31.5 million and intangible assets of $11.3 million based on their estimated fair values at the purchase date. No liabilities were assumed in connection with the
purchase.The Company believes that the fair values assigned to the assets acquired and the contingent consideration were based on reasonable assumptions.The useful life of the intangible assets was determined to be 10.0 years.The
Company currently estimates that a substantial portion of the goodwill acquired will be deductible for income tax purposes.As of December31, 2010, the total estimated fair value of the contingent consideration was $44.5million, of
which $3.2 million was included in Accounts payable and $41.3 million was included in Other liabilities. </font></p><p style="margin-top:12px;margin-bottom:0px; margin-left:4%"><font size="2" style="font-family:Times New Roman"><b><i>Serica Acquisition </i></b></font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">On January15, 2010, the
Company completed the acquisition of Serica, a development stage medical device company based in the United States focused on developing biodegradable silk-based scaffolds for use in tissue regeneration for breast reconstruction, for an aggregate
purchase price of approximately $63.7million, net of cash acquired.In connection with the acquisition, the Company acquired assets with a fair value of $96.0million and assumed liabilities of $32.3million.The
acquisition was funded from current cash and equivalents balances.The Serica acquisition provides the Company with an approved technology that has potential future application in breast augmentation, revision surgeries, as well as potential
bariatric applications.</font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">The Company recognized tangible and intangible assets acquired and liabilities assumed
in connection with the Serica acquisition based on their estimated fair values at the acquisition date.The excess of the purchase price over the fair value of net assets acquired was recognized as goodwill.The goodwill acquired in the
Serica acquisition is not deductible for federal income tax purposes.</font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">The Company believes the fair values
assigned to the Serica assets acquired and liabilities assumed were based on reasonable assumptions.The following table summarizes the estimated fair values of net assets acquired: </font></p><p style="font-size:12px;margin-top:0px;margin-bottom:0px"></p><table align="center" border="0" cellpadding="0" cellspacing="0" width="84%">
<tr>
<td width="86%"></td>
<td valign="bottom" width="7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>(inmillions)</b></font></td>
<td valign="bottom"><font size="1"></font></td></tr>
<tr bgcolor="#cceeff">
<td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Identifiable intangible assets</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">71.4</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr>
<td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Goodwill</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">13.2</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr bgcolor="#cceeff">
<td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Property, plant and equipment</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">0.7</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr>
<td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Deferred tax assets  non-current</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">10.7</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr bgcolor="#cceeff">
<td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Accounts payable and accrued liabilities</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">(3.1</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td></tr>
<tr>
<td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Notes payable</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">(3.4</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td></tr>
<tr bgcolor="#cceeff">
<td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Deferred tax liabilities non-current</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">(25.8</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td></tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td></tr>
<tr>
<td valign="top"></td>
<td valign="bottom"><font size="1"></font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">63.7</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td></td></tr></table><tr>
<td width="86%"></td>
<td valign="bottom" width="7%"></td>
<td></td>
<td></td>
<td></td></tr><td width="86%"></td><tr>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>(inmillions)</b></font></td>
<td valign="bottom"><font size="1"></font></td></tr><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="1"></font></td><td align="center" colspan="2" valign="bottom"><font size="1" style="font-family:Times New Roman"><b>(inmillions)</b></font></td><td valign="bottom"><font size="1"></font></td><tr bgcolor="#cceeff">
<td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Identifiable intangible assets</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">71.4</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr><td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Identifiable intangible assets</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Identifiable intangible assets</font></p><td valign="bottom"><font size="1"></font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td><td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">71.4</font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><tr>
<td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Goodwill</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">13.2</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr><td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Goodwill</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Goodwill</font></p><td valign="bottom"><font size="1"></font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">13.2</font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><tr bgcolor="#cceeff">
<td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Property, plant and equipment</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">0.7</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr><td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Property, plant and equipment</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Property, plant and equipment</font></p><td valign="bottom"><font size="1"></font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">0.7</font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><tr>
<td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Deferred tax assets  non-current</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">10.7</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr><td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Deferred tax assets  non-current</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Deferred tax assets  non-current</font></p><td valign="bottom"><font size="1"></font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">10.7</font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><tr bgcolor="#cceeff">
<td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Accounts payable and accrued liabilities</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">(3.1</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td></tr><td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Accounts payable and accrued liabilities</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Accounts payable and accrued liabilities</font></p><td valign="bottom"><font size="1"></font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">(3.1</font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td><tr>
<td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Notes payable</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">(3.4</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td></tr><td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Notes payable</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Notes payable</font></p><td valign="bottom"><font size="1"></font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">(3.4</font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td><tr bgcolor="#cceeff">
<td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Deferred tax liabilities non-current</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td>
<td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">(25.8</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td></tr><td nowrap="" valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Deferred tax liabilities non-current</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font size="2" style="font-family:Times New Roman">Deferred tax liabilities non-current</font></p><td valign="bottom"><font size="1"></font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">(25.8</font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">)</font></td><tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td></tr><td valign="bottom"></td><td valign="bottom"></td><td style="border-top:1px solid #000000" valign="bottom"></td><tr>
<td valign="top"></td>
<td valign="bottom"><font size="1"></font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td>
<td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">63.7</font></td>
<td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td></tr><td valign="top"></td><td valign="bottom"><font size="1"></font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">$</font></td><td align="right" nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman">63.7</font></td><td nowrap="" valign="bottom"><font size="2" style="font-family:Times New Roman"></font></td><tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td></td></tr><td valign="bottom"></td><td valign="bottom"></td><td style="border-top:3px double #000000" valign="bottom"></td><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">The acquired identifiable intangible assets consist of $67.1 million in developed technology
related to a medical device approved in the United States that aids in the repair and reinforcement of human soft tissue and an in-process research and development asset of $4.3 million related to a dermal filler technology that has not yet achieved
regulatory approval.The useful life of the developed technology was determined to be approximately 11.8 years.Future impairment evaluations for the developed technology will occur at a consolidated cash flow level within the
Companys medical devices segment in the United States, the market used to originally value the intangible asset.The in-process research and development asset is classified as an indefinite-lived intangible asset until the successful
completion and commercialization or abandonment of the associated research and development efforts.</font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">F-14
</font></p><p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>ALLERGAN, INC. </b></font></p><p align="center" style="margin-top:6px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS  (Continued) </b></font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; margin-left:4%"><font size="2" style="font-family:Times New Roman"><b><i>Samil Acquisition </i></b></font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">On July7, 2009, the Company and Samil Pharmaceutical Co. Ltd. entered into a joint venture, Samil Allergan
Ophthalmic Joint Venture Company (Samil), in Korea by integrating the Samil Eyecare division with the Companys Korean ophthalmology products.In addition, the Company paid approximately $16.3 million ($14.8 million, net of cash acquired)
to Samil Pharmaceutical Co. Ltd. to acquire the Companys joint venture investment and received a 50.001% stockholder interest in the joint venture.The acquisition was funded from cash and equivalents balances.The Company accounted
for the Samil acquisition as a business combination.</font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">In connection with the Samil acquisition, the Company
acquired assets with a fair value of $40.8 million, including goodwill of $24.7 million, intangible assets of $5.1 million, cash of $1.5 million and other assets of $9.5 million, and assumed liabilities of $8.1million.The Company
believes the fair values assigned to the assets acquired and liabilities assumed were based on reasonable assumptions.In the first quarter of 2010, the Company increased goodwill by $1.7 million due to a contractual purchase price adjustment.
</font></p><p style="margin-top:12px;margin-bottom:0px; margin-left:4%"><font size="2" style="font-family:Times New Roman"><b><i>Collaborations </i></b></font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">In March 2010, the Company and Serenity Pharmaceuticals, LLC (Serenity) entered into an agreement for the license, development and commercialization of a Phase III investigational drug currently in
clinical development for the treatment of nocturia, a common urological disorder in adults characterized by frequent urination at night time.Under the terms of the agreement, the Company receives exclusive worldwide rights to develop,
manufacture and commercialize the investigational drug for all potential indications except Primary Nocturnal Enuresis (pediatric bedwetting).In conjunction with the agreement, the Company agreed to make an upfront payment to Serenity of $43.0
million, which was paid in the second quarter of 2010.The terms of the agreement also include potential future development and regulatory milestone payments to Serenity of up to $122.0 million, as well as potential future sales milestone and
royalty payments.Because the technology has not yet achieved regulatory approval, the Company recorded the upfront payment of $43.0 million as research and development (R&amp;D) expense in the first quarter of 2010. </font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">In December 2010, the Company and Serenity executed a letter agreement which specified certain terms and conditions
governing additional development activities for a new Phase III trial which were not set forth in the original agreement. Under the letter agreement, the Company has agreed to share 50% of the cost of additional development activities. The execution
of the letter agreement was a reconsideration event for the Companys variable interest in the collaboration agreement with Serenity, and since the Company is providing a significant amount of the funding for the new Phase III trial, it
determined that Serenity has become a VIE. However, the Company determined that it is not the primary beneficiary of the VIE because it does not possess the power to direct Serenitys research and development activities, which are the
activities that most significantly impact Serenitys economic performance. The Companys maximum exposure to loss is the upfront payment of $43.0 million made to Serenity and any future shared costs of additional development activities.
</font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">In March 2010, the Company and Bristol-Myers Squibb Company (Bristol-Myers Squibb) entered into an agreement
for the development and commercialization of an investigational drug for neuropathic pain.Under the terms of the agreement, the Company granted to Bristol-Myers Squibb exclusive worldwide rights to develop, manufacture, and commercialize the
investigational drug for neuropathic pain and backup compounds.In conjunction with the agreement, the Company agreed to receive a net upfront payment of $36.0 million, which was collected in the second quarter of 2010.The terms of the
agreement also include potential future development and regulatory milestone payments to the Company of up to $373.0 million, as well as potential future royalty payments.The Company recorded the net upfront receipt of $36.0 million as other
revenue in the first quarter of 2010.</font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">F-15
</font></p><p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>ALLERGAN, INC. </b></font></p><p align="center" style="margin-top:6px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS  (Continued) </b></font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="justify" style="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><font size="2" style="font-family:Times New Roman">In March 2010, the Company amended its existing
license agreements with GlaxoSmithKline (GSK) to reacquire the distribution rights to<i> Botox</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> for all
current and future cosmetic indications in Japan and China for $18.5 million, which was paid in the third quarter of 2010.The Company capitalized the value of these reacquired rights as an intangible asset in the first quarter of
2010.</font></p><i> Botox</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><font size="2" style="font-family:Times New Roman">In September 2010, the Company acquired from Vistakon Pharmaceuticals, LLC, Janssen
Pharmaceutica N.V., Beerse and Johnson&amp; Johnson Vision Care Inc. the global license to manufacture and commercialize alcaftadine 0.25%, a topical allergy medication for the prevention and treatment of itching associated with allergic
conjunctivitis.In conjunction with the license agreement for this product that was approved in July 2010 for marketing in the United States under the brand name <i>Lastacaft</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> (alcaftadine ophthalmic solution), the Company agreed to make an upfront payment of $23.0 million, which was paid in the fourth quarter of 2010.The terms of
the agreement also require the Company to make potential future regulatory milestone payments of up to $12.0 million, as well as future royalty payments.The Company capitalized $22.4 million of the upfront licensing payment as an intangible
asset in the third quarter of 2010. </font></p><i>Lastacaft</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><p style="margin-top:12px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>Note3:Restructuring Charges and Integration Costs </b></font></p><p style="margin-top:12px;margin-bottom:0px; margin-left:4%"><font size="2" style="font-family:Times New Roman"><b><i>2009 Restructuring Plan </i></b></font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><font size="2" style="font-family:Times New Roman">On February4, 2009, the Company announced a restructuring plan that involved a workforce
reduction of approximately 460 employees, primarily in the United States and Europe.The majority of the employees affected by the restructuring plan were U.S. urology sales and marketing personnel as a result of the Companys decision to
focus on the urology specialty and to seek a partner to promote <i>Sanctura XR</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font> to general practitioners,
and furthermore marketing personnel in the United States and Europe as the Company adjusted its back-office structures to a reduced short-term sales outlook for some businesses.The restructuring plan also included modest workforce reductions
in other functions as the Company re-engineered its processes to increase efficiency and productivity.</font></p><i>Sanctura XR</i><font size="1" style="font-family:Times New Roman"><sup style="vertical-align:baseline; position:relative; bottom:.8ex"></sup></font><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">As part
of the restructuring plan, the Company modified the outstanding stock options issued in its February 2008 full-round employee stock option grant.The stock options were originally granted with an exercise price of $64.47 with a standard four
year graded vesting term, a ten year contractual term, and standard 90 day expiration upon termination of employment provisions.These options were modified to be immediately vested in full and to remove the 90 day expiration upon termination
of employment provision.Because the modified awards became fully vested and there was no future derived service period, all unamortized compensation expense related to the original grant and the additional compensation expense attributable to
the modification of the awards was recognized in full on the modification date.</font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">In addition, the contractual
provisions of outstanding stock options, other than the February 2008 full-round employee stock option grant, held by employees impacted by the workforce reduction were modified to extend the stock option expiration dates.Under the original
contractual provisions, outstanding stock options held by employees involved in a workforce reduction automatically become fully vested upon termination of employment and the stock options expire after the earlier of 90 days from termination of
employment or the remaining stock option contractual term.Under the modified terms, stock options for the impacted employees will expire after the earlier of three years from termination of employment or the remaining contractual
term.All unamortized compensation expense related to the original stock option awards plus the incremental compensation expense associated with the modifications was recognized ratably from the modification date to the employees expected
termination date.The fair value of the modifications to all share-based awards was generally estimated using a lattice model.The total incremental pre-tax compensation expense associated with the modifications attributable to the 2009
restructuring plan was $11.0 million. </font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman">F-16
</font></p><p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p align="center" style="margin-top:0px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>ALLERGAN, INC. </b></font></p><p align="center" style="margin-top:6px;margin-bottom:0px"><font size="2" style="font-family:Times New Roman"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS  (Continued) </b></font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="justify" style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">The Company began to record costs associated with the 2009 restructuring
plan in the first quarter of 2009 and substantially completed all activities related to the restructuring plan in the second quarter of 2009.The restructuring charges primarily consist of employee severance and other one-time termination
benefits.During 2009, the Company recorded pre-tax restructuring charges of $42.2 million and recognized a total of $78.6 million related to employee stock option modifications, consisting of $5.0 million of cost of sales, $52.6 million in
SG&amp;A expenses and $21.0 million in R&amp;D expenses, and recognized $2.3 million of asset write-offs and accelerated depreciation costs in SG&amp;A expenses.</font></p><p style="margin-top:12px;margin-bottom:0px; margin-left:4%"><font size="2" style="font-family:Times New Roman"><b><i>Restructuring and Phased Closure of Arklow Facility </i></b></font></p><p align="justify" style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font size="2" style="font-family:Times New Roman">On January30, 2008, the Company announced the phased closure of its breast implant manufacturing facility at
Arklow, Ireland and the transfer of production to the Companys manufacturing plant in Costa Rica.The Arklow facility was acquired by the Company in connection with its 2006 acquisition of Inamed Corporation (Inamed) and employed
approximately 360people.As of March31, 2009, all production activities at the Arklow facility had ceased.Certain employee retention termination benefits and accelerated depreciation costs related to inventory production in
Arklow were capitalized to inventory as incurred and recognized as cost of sales in the periods the related products were sold. </font></p>